EGFR and chronic myelogenous leukemia, BCR-ABL1 positive: They also promoted antiproliferative activity in triple-negative breast cancer cells [10], nonautophagic cell death in human lung adenocarcinoma cells with an epidermal growth factor receptor (EGFR) mutation [11], and anticancer activity via apoptosis in chronic myeloid leukemia cells using a transcriptomic approach [12].